SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: John O'Neill who wrote (18944)4/12/1998 11:53:00 AM
From: JOEBT1  Read Replies (2) | Respond to of 32384
 
Jo
There's lots of news on the horizon for LGND. Panretin NDA in 2Q; TSE424 trials to begin in 2Q; NDA for topical Targretin in 2Q/3Q; LLY compound choice in 2Q; Phase II Targretin breast cancer trial start in 2Q; Results from lung cancer, breast cancer(NCI trial), kidney cancer, prostate cancer,ovarian cancer PhaseII trials in 2Q/3Q; Psoriasis PhaseII in 3Q/4Q; Start of Phase II LLy diabetes in 2Q; etc, etc.
All the above gleamed from H&Q, Robertson Stephens reports and other posts.



To: John O'Neill who wrote (18944)4/12/1998 9:13:00 PM
From: tonyt  Read Replies (1) | Respond to of 32384
 
>I just didn't want to wait for a buy at $14, while having no LGND, & watch
>it go to $25 and then hear the news.

LGND has gone to $9 and then $11 while we're waiting for $25.
Why will this time be different?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News